We found that deficits in beam-walking (Figure 3A and B), corner tests (Figure 3C), elevated body swing (Figure 4A), limb-placing (Figure 4B), and rotarod (Figure 4C) were worse in the GCV-treated middle-aged DCX-TK(+) transgenic mice tested up to 4 weeks after dMCAO, compared to vehicle-treated DCX-TK(+) and vehicle- or GCV-treated DCX-TK(−) mice, suggesting involvement of newly generated cells in functional outcome after focal ischemia. This evidence concerns the gene TKT and ischemia.